Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Boston Scientific Q3 2026 Results: Net Income $580M, Down 23.2% YoY

Boston Scientific reported net sales of $5.138 billion for the third quarter of 2026, a slight increase from $5.065 billion in the prior year period. Net income attributable to common stockholders decreased to $582 million ($0.40 per diluted share) compared to $755 million ($0.51 per diluted share) in Q3 2025, impacted by higher operating expenses and litigation-related charges.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue5,138.05,065.0
Gross profit3,428.03,542.0
Profit before tax733.0939.0
Net income580.0755.0
EPS (diluted, $ a share)$0.40$0.51

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-23.2%
Revenue, year on year+1.4%
Gross margin66.7%
Operating margin16.1%
Source

10-Q filed with the SEC, NYSE: BSX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Boston Scientific Corp: key numbers

Share price
$43.69Close, Nov 16
Market cap
$63.3B
Shares outstanding
1.45BLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Boston Scientific Corp

All →
4:09 PM ET 8-K
Executive Compensation

Boston Scientific Executive Compensation

Boston Scientific's Board approved the 2027 Annual Bonus Plan, a cash incentive program for eligible employees and named executive officers based on global sales and adjusted EPS targets. The plan features a distribution percentage range of 0% to 150% and individual performance modifiers, allowing for a maximum payout of 225% of target bonus. The Board also approved the adoption of two new performance share programs for the 2027 performance year.

Term
1 year
6:35 AM ET 8-K
Financial Results

Boston Scientific Financial Results

Boston Scientific reported Q3 2026 net sales of $5.138 billion, representing 1.5% organic growth despite operational challenges from a previously disclosed cybersecurity incident. The company achieved GAAP EPS of $0.40 and adjusted EPS of $0.73, while continuing to advance its pipeline with new FDA clearances for its StoneSmart and SEISMIQ technologies.

“This has been a challenging year for Boston Scientific and I’m proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients. As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation.”

Mike Mahoney, chairman and chief executive officer, Boston Scientific
6:12 AM ET 8-K
Executive Compensation

Boston Scientific Executive Compensation

Boston Scientific promoted Joe Fitzgerald to Executive Vice President and Chief Operating Officer, effective January 1, 2027. The company disclosed his new compensation package, including a $1.05 million base salary, a 110% target bonus, and a 2027 annual equity award valued at $7.0 million. The appointment coincides with a new operating structure consisting of three reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg.

6:03 AM ET 8-K
Leadership Change

Boston Scientific Leadership Change

Arthur C. Butcher, Executive Vice President and Group President of MedSurg and Asia Pacific, has announced his retirement effective January 1, 2027. He will serve as a senior advisor through February 26, 2027, maintaining his current annual base salary of $780,000 during the transition period.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.